Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia 1

Patients Using Generative Artificial Intelligence 2

Jan-Niklas Eckardt,^{1,2} Waldemar Hahn,^{3,4} Christoph Röllig,¹ Sebastian Stasik,¹ Uwe Platzbecker,⁵ 3

Carsten Müller-Tidow,⁶ Hubert Serve,⁷ Claudia D. Baldus,⁸ Christoph Schliemann,⁹ Kerstin Schäfer-4

- Eckart,¹⁰ Maher Hanoun,¹¹ Martin Kaufmann,¹² Andreas Burchert,¹³ Christian Thiede,¹ Johannes 5
- Schetelig,¹ Martin Sedlmayr,⁴ Martin Bornhäuser,^{1,14,15} Markus Wolfien,^{3,4} and Jan Moritz Middeke^{1,2} 6
- 7 ¹ Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden,
- 8 Germany
- 9 ² Else Kröner Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany
- 10 ³ Center for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Germany
- 11 ⁴ Institute for Medical Informatics and Biometry, Technical University Dresden, Dresden, Germany
- 12 ⁵ Medical Clinic and Policlinic I Hematology and Cell Therapy. University Hospital, Leipzig, Germany
- 13 ⁶ Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
- 14 ⁷ Department of Medicine 2, Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany
- 15 ⁸ Department of Hematology and Oncology, University Hospital Schleswig Holstein, Kiel, Germany
- 16 ⁹ Department of Medicine A, University Hospital Münster, Münster, Germany
- 17 ¹⁰ Department of Internal Medicine V, Paracelsus Medizinische Privatuniversität and University Hospital Nürnberg,
- 18 Nürnberg, Germany
- 19 ¹¹ Department of Hematology, University Hospital Essen, Essen, Germany
- 20 ¹² Department of Hematology, Oncology and Palliative Care, Robert-Bosch-Hospital, Stuttgart, Germany
- 21 ¹³ Department of Hematology, Oncology and Immunology, Philipps-University-Marburg, Marburg, Germany
- 22 ¹⁴ German Consortium for Translational Cancer Research DKFZ, Heidelberg, Germany
- 23 ¹⁵ National Center for Tumor Diseases (NCT), Dresden, Germany
- 24 Running title: Synthetic leukemia data with generative AI
- Key words: acute myeloid leukemia, AML, synthetic data, generative model, artificial intelligence 25
- Correspondence: Jan-Niklas Eckardt, MD, MSc; Department of Internal Medicine I, University 26
- Hospital Carl Gustav Carus, Technical University Dresden and Else-Kröner-Fresenius Center for Digital 27
- 28 Health, Technical University Dresden, Fetscherstraße 74, 01307 Dresden Germany; phone: +49 351 458
- 11542; e-mail: jan-niklas.eckardt@uniklinikum-dresden.de. 29
- 30
- Word count, abstract: 194; word count, main text: 3876, figures/tables: 6; supplementary figures/tables: 31
- 10; references: 39 32
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 33

34 Graphical Abstract



35

36 Abstract

Clinical research relies on high-quality patient data, however, obtaining big data sets is costly and access 37 to existing data is often hindered by privacy and regulatory concerns. Synthetic data generation holds 38 39 the promise of effectively bypassing these boundaries allowing for simplified data accessibility and the 40 prospect of synthetic control cohorts. We employed two different methodologies of generative artificial 41 intelligence – CTAB-GAN+ and normalizing flows (NFlow) – to synthesize patient data derived from 42 1606 patients with acute myeloid leukemia, a heterogeneous hematological malignancy, that were 43 treated within four multicenter clinical trials. Both generative models accurately captured distributions 44 of demographic, laboratory, molecular and cytogenetic variables, as well as patient outcomes yielding 45 high performance scores regarding fidelity and usability of both synthetic cohorts (n=1606 each). 46 Survival analysis demonstrated close resemblance of survival curves between original and synthetic 47 cohorts. Inter-variable relationships were preserved in univariable outcome analysis enabling 48 explorative analysis in our synthetic data. Additionally, training sample privacy is safeguarded mitigating possible patient re-identification, which we quantified using Hamming distances. We provide 49 not only a proof-of-concept for synthetic data generation in multimodal clinical data for rare diseases, 50 51 but also full public access to synthetic data sets to foster further research.

52 **Introduction**

53 In the age of big data, the paucity of publicly available medical data sets is often staggering. Despite 54 extensive data collection efforts, such as The Cancer Genome Atlas(1), the public availability of 55 comprehensive entity-specific data sets remains largely unsatisfactory. Data sharing is often hindered 56 by concerns of patient privacy, regulatory aspects, and proprietary interests.(2) These factors do not only 57 impede progress in medical research but also establish a gatekeeping mechanism that restricts specific 58 research inquiries to large institutions with access to extensive datasets. Collecting such data sets is a 59 costly and time-consuming effort and especially later-phase clinical trials usually take years to complete 60 and require millions in funding.(3,4) In particular, this is true for rare diseases, such as acute myeloid 61 leukemia (AML), which is a genetically heterogenous and highly aggressive hematological malignancy 62 with so far unsatisfactory patient outcomes despite recent advances in therapy.(5) In addition, the 63 development of targeted therapies for defined subgroups leads to an increased need for control groups.(6) To gain insights into such burdensome malignant entities with unmet medical needs, a crowd-64 sourcing of data to refine risk stratification efforts and test treatment-related hypothesis is essential. If 65 66 machine learning methods are to be deployed in such data sets, the size of available diverse training data 67 is paramount for model robustness. Generative models, especially generative adversarial neural networks (GANs)(7), have exhibited remarkable capabilities in image generation(8), but can also 68 effectively generate synthetic non-image data. The unique properties of generative artificial intelligence 69 70 (AI) yield the prospect of synthesizing data based on real patients, which can be distributed at will since, 71 ideally, synthetic data only mimics real patient data alleviating concerns of privacy. In this scenario, the 72 synthetic data itself should preserve the biological characteristics of the disease under investigation to make inferences to real-world applications possible. At the same time, synthetic data should safeguard 73 74 privacy of the underlying training cohort.

In this study, we employ two state-of-the-art technologies of generative modeling on a large training data set of four pooled multicenter clinical trials including AML patients with comprehensive clinical and genetic information. We investigate how closely the synthetic data resembles the real trial data aligning baseline characteristics and patient outcome. Further, we measure privacy conservation in the

synthetic data. Additionally, we provide both final fully synthetic data sets comprising 1606 AML
patients each in a publicly accessible repository to foster further research into this devastating disease.

81

82 Methods

83 **Patient data**

Multimodal clinical, laboratory, and genetic data (Table S1) were obtained from 1606 patients with non-84 85 M3 AML that were treated within previously conducted multicentric prospective clinical trials of the German Study Alliance Leukemia (SAL; AML96 [NCT00180115](9), AML2003 [NCT00180102](10), 86 87 AML60+ [NCT00180167](11), and SORAML [NCT00893373](12)). Table S2 shows an overview of 88 trial protocols. Eligibility was determined upon diagnosis of AML, age ≥ 18 years, and curative treatment 89 intent. All patients gave their written informed consent according to the revised Declaration of Helsinki.(13) All studies were previously approved by the Institutional Review Board of the Technical 90 91 University Dresden. Complete remission (CR), event-free survival (EFS), and overall survival (OS) 92 were defined according to the revised ELN criteria.(14) Biomaterial was obtained from bone marrow 93 aspirates or peripheral blood prior to treatment initiation. Next-Generation Sequencing (NGS) was performed using the TruSight Myeloid Sequencing Panel (Illumina, San Diego, CA, USA). Pooled 94 samples were sequenced paired-end and a 5% variant allele frequency (VAF) mutation calling cut-off 95 was used with human genome build HG19 as a reference as previously described in detail.(15) 96 Additionally, high resolution fragment analysis for FLT3-ITD(16), NPM1(17), and CEBPA(18) was 97 98 performed as described previously. For cytogenetics, standard techniques for chromosome banding and 99 fluorescence-in-situ-hybridization (FISH) were used.

100

101 *Generative models*

In our study, we used two state-of-the-art generative models exhibiting two fundamentally differentconcepts of data generation:

i) CTAB-GAN+(19) builds upon the Generative Adversarial Network (GAN)(20) architecture,
consisting of two interlinked neural networks - the generator and the discriminator. These are jointly
trained in an adversarial manner. The generator's goal is to produce synthetic data that appears realistic,
starting from random noise. In parallel, the discriminator seeks to differentiate between real and
synthetic samples created by the generator. The training continues until the discriminator is no longer
able to reliably distinguish real data from synthetic, indicating that the generator has successfully
approximated the distribution of the real data.

111 ii) Normalizing Flows (NFlow)(21) presents an alternative approach for synthesizing data from complex 112 distributions. This comprises a sequence of invertible transformations, starting from a simple base distribution. Each transformation, or 'flow', gradually modifies this base distribution into a more 113 complex one that better mirrors the actual data. Importantly, these transformations are stackable, 114 115 meaning they can be applied successively to incrementally increase the complexity of the modeled 116 distribution. All parameters defining these flows are learned directly from the data, allowing the model 117 to accurately capture the underlying data distribution. Note, that we used a modification of NFlow for survival data provided by the Syntheity(22) software framework. 118

No imputation of missing data was performed in the original data set, thus both final synthetic data sets also contain missing data to adequately represent real-world conditions. Hyperparameter tuning was performed using the Optuna framework allowing both generative models to capture the best possible representation of the original data. Afterwards, we trained each model with five different random seeds and sampled from it three times, which generated 15 synthetic datasets for each model. Results are reported for each highest-performing synthetic data set, respectively.

125

126 *Evaluation of synthetic data performance*

To assess the fidelity und usability of synthetic data, previously proposed evaluation metrics were used to provide a comprehensive overview of model performance. In particular, Basic Statistical Measure, Regularized Support Coverage, and Log-transformed Correlation Score were used to evaluate the fidelity of the data in general via our implementation based on the descriptions by Chundawat et al.(23).

The second set of metrics – Kaplan-Meier-Divergence, Optimism and Short-Sightedness - was previously introduced by Norcliffe et al.(24) for synthetic survival data, and implemented in Synthetity(22). For improved comparability, performance metrics were normalized on a scale from 0 (inadequate representation of original data) to 1 (optimal representation). An overview of the underlying methodologies of these metrics is provided in Table S3. For detailed information, we refer the interested reader to the original publications.(23,24)

137

138 Assessment of privacy conservation

139 To assess potential privacy implications of synthetic data, we customized the method proposed by 140 Platzer and Reutterer(25) to accommodate for smaller sample sizes. We partitioned the original training 141 data (80% of total) into four subsets, matching the size of the test dataset (20%) for balanced comparisons (Fig. S1). Calculations were performed using Hamming distance(26) for categorical 142 features. Numerical variables were binned (n=10 bins each) and thereby categorized to enable Hamming 143 distance calculations. Given the nature of the Hamming distance metric, the average minimum distance 144 effectively denotes the number of variables that would need to be altered for a synthetic patient to match 145 146 a real patient. We compared the average distances of the synthetic data to the training (syn \rightarrow train) and test sets (syn \rightarrow test). The relationship between both can be expressed as a coefficient for each synthetic 147 148 data set compared to training and test set:

149
$$privacy \ leakage \ coefficient = \frac{syn \to test}{syn \to train} - 1$$

By analyzing whether the synthetic data is closer to the training set compared to the test set, we can assess whether the synthetic data is overly representative of the training data, thereby posing potential privacy concerns. If the average distances from the synthetic data to the training and test data are equally small, the privacy leakage coefficient will also be small. The lower the privacy leakage coefficient, the lower the likelihood of re-identification for patients in the training set. We assumed that values above 0.05 signal potential privacy breaches, as they suggest the synthetic data is substantially closer to the training set than to the test set. Conversely, values below 0.05 denote a favorable privacy safeguard,

157 signaling similar distances between the training and test sets. Additionally, the number of exact subject158 matches between the synthetic and original cohorts was determined.

159

160 Statistical analysis

161 Pairwise analyses were conducted between the original and both synthetic data sets. Normality was 162 assessed using the Shapiro-Wilk test. If the assumption of normality was met, continuous variables 163 between two samples were analyzed using the two-sided unpaired t-test. If the assumption of normality was violated, continuous variables between two samples were analyzed using the Wilcoxon rank sum 164 165 (syn. Mann-Whitney) test. Fisher's exact test was used to compare categorical variables. Univariate 166 analyses for binary outcomes (CR rate) were carried out via logistic regression to obtain odds ratios 167 (OR) and 95% confidence intervals (95%-CI). Time-to-event analyses (EFS, OS) were carried out using Cox proportional hazard models to obtain hazard ratios (HR) and 95%-CI. Kaplan-Meier analyses were 168 performed for time-to-event data (EFS, OS) and corresponding log-rank tests are reported. Median 169 follow-up time was calculated using the reverse Kaplan-Meier method.(27) All tests were carried out as 170 171 two-sided tests. Statistical significance was determined using a significance level α of 0.05. Statistical 172 analysis was performed using STATA BE 18.0 (Stata Corp, College Station, TX, USA).

173

174 Data availability

- The final synthetic data sets generated and analyzed for the purpose of this study are publicly available
 at https://zenodo.org/record/8334265
- 177
- 178 *Code availability*

179 The code generated for the purpose of this study is publicly available at https://github.com/waldemar93/synthetic data pipeline 180

Results 182

183 Synthetic cohorts generated by CTAB-GAN+ and NFlow score highly in fidelity metrics

184 We generated equally sized data sets of n=1606 synthetic patients with each generative model to compare patient variables to the original cohort. The fidelity of synthetic data was assessed with three 185 186 previously proposed performance metrics scaled from 0 (inadequate representation) to 1 (optimal representation). First, the distribution of each individual variable was compared between original and 187 synthetic data again yielding high scores for both models (Regularized Support Coverage(23) for 188 189 CTAB-GAN+: 0.95 and NFlow: 0.97). Second, continuous numerical variables were assessed by 190 comparing mean, median, and standard deviation between original and synthetic data per variable (Basic Statistical Measure(23)) showing high scores for both CTAB-GAN+ (0.91) and NFlow (0.92). Third, 191 regarding accurate representations of inter-variable correlations, CTAB-GAN+ and NFlow achieved a 192 193 Log-Transformed Correlation Score(23) of 0.75 and 0.74, respectively. An overview of performance 194 metrics is provided in Tab. S4 (usability; survival metrics are reported with survival analysis).

195

Synthetic clinical and genetic patient characteristics closely mimic those of real patients 196

Baseline patient characteristics compared between real and synthetic patients are shown in Table 1. It 197 has to be noted that given the large sample sizes (three groups with n=1606 each), even small effect 198 199 sizes yield statistically significant differences. For instance, median age in the original cohort was 56 200 years, while synthetic patients generated by CTAB-GAN+ had a slightly younger median age of 53 201 years (p=0.0001), whereas NFlow-generated patients had a slightly older median age of 58 years 202 (p=0.039). Sex distribution did not differ between NFlow and the original cohort, while CTAB-GAN+ 203 generated more males than females (NFLOW: 56.2% vs. 43.8%; original: 52.2% vs. 47.8%; p=0.023). 204 The rates of *de novo*, secondary, and therapy-associated AML did not differ significantly for CTAB-205 GAN+ generated patients, while NFlow generated fewer de novo and more therapy-associated AML 206 patients compared to the original cohort. Hemoglobin levels and platelet count did not differ 207 significantly between the original and the synthetic cohorts, while synthetic patients generated by 208 CTAB-GAN+ showed a significantly higher median white blood cell count than the original cohort.

209 Fifty molecular and cytogenetic alterations were included in generating synthetic patients. Figure 1 210 displays the distribution of these alterations across the original and synthetic cohorts (absolute numbers 211 and *p*-values are provided in Tab. S5). These alterations encompass genes that code for epigenetic regulators (Fig. 1A), the cohesin complex (Fig. 1B), transcription factors (Fig. 1C), TP53 and 212 Nucleophosmin 1 (Fig. 1D), signaling factors (Fig. 1E), components of the spliceosome (Fig. 1F), and 213 214 cytogenetic aberrations with established impact on patient outcome (Fig. 1G). Overall, the rates of 215 alterations in both synthetic cohorts were in a plausible range with a few deviations from the original 216 cohort of high statistical significance, such as NFlow-generated frequencies of BCORL1, DNMT3A, 217 PHF6, and ZRSR2, as well as CTAB-GAN+-generated frequencies of CUX1 and GATA2 while the remainder of alterations showed only negligible differences. Aside from the frequency per individual 218 219 alteration, the co-occurrences of alterations play an important role in disease biology, which should be also captured in high-quality synthetic data. Fig. 2 shows the relative differences between the original 220 221 cohort and CTAB-GAN+ (Fig. 2A) and NFlow (Fig. 2B) regarding co-occurring mutations. We found 222 high congruencies for co-occurrences compared to the original cohort, while deviations were commonly found in alterations that had a low frequency in the original cohort. 223

224

225 Synthetic cohorts match real patients in outcome and survival analysis

Median follow-up for the original cohort was 89.5 months (95%-CI: 85.5-95.4). The synthetic cohorts 226 227 had a median follow-up of 91.3 months (CTAB-GAN+, 95%-CI: 84.8-98.0) and 74.3 months (NFlow, 228 95%-CI: 70.9-77.4). Table 2 shows a detailed comparison of patient outcome between the original and 229 both synthetic cohorts. For CR rates, we found no significant differences between the original (70.7%) and both synthetic cohorts (CTAB-GAN+: 73.7%; NFlow: 69.1%). Median EFS in the original cohort 230 231 was 7.2 months while both CTAB-GAN+ with 12.8 months and NFlow with 9.0 months deviated with 232 high significance. This effect can arguably be attributed to both CR rate and OS being included in hyperparameter tuning, while EFS was exempt from hyperparameter tuning. Kaplan-Meier analysis 233 nevertheless showed a plausible representation of the survival curves for both synthetic cohorts 234 235 regarding EFS (Fig. 3A). Median OS for the original cohort was 17.5 months while the CTAB-GAN+

236 cohort had a median OS of 19.5 months (p<0.0001) and NFlow of 16.2 months (p=0.055). Kaplan-Meier 237 analysis (Fig. 3B) showed similar behavior of survival curves as for EFS. This was also evident with 238 regard to usability metrics for synthetic survival data introduced by Norcliffe et al.(24): We found both 239 CTAB-GAN+ and NFlow to score high in our test set with normalized performance results (+1 is optimal representation, 0 is inadequate representation, Tab. S4). Kaplan-Meier-Divergence, i.e. the 240 degree to which survival curves of synthetic and real data differ, was low for both synthetic data sets 241 242 (CTAB-GAN+: 0.97, NFlow: 0.98). Neither model showed overt optimism or overt pessimism in 243 representing survival data (CTAB-GAN+: 0.98, NFlow: 0.99). For both EFS and OS, the curve of CTAB-GAN+ showed no stabilization of survival rates towards the end of the follow-up period in 244 comparison to the curve of the original cohort while NFlow tends to censor a higher rate of patients after 245 passing the 2-year follow-up mark. Nonetheless, Short-sightedness, i.e. failure to predict beyond a 246 247 certain time point, was also low for both models, however slightly favoring CTAB-GAN+ over NFlow (CTAB-GAN+: 0.99, NFlow: 0.93) arguably corresponding to the censoring tendency of NFlow. 248

249

250 Synthetic data captures risk associations of individual variables for explorative analyses

251 In order to be useful for explorative analyses, synthetic data needs to recapitulate risk associations of individual variables. The ELN2022 recommendations represent one of the most widely used guidelines 252 253 for risk stratification.(14) Hence, previously established markers of favorable (normal karyotype, 254 t(8;21), inv(16) or t(16;16) mutations of NPM1, CEBPA-bZIP in frame mutations), intermediate risk 255 (FLT3-ITD, t(9;11)), or adverse risk (complex karyotype, -5, del(5q), -7, -17, mutations of TP53, RUNX1, ASXL1), and age were evaluated using univariable analyses per cohort for their impact on 256 257 achievement of CR, EFS, and OS. All effects for achievement of CR, EFS, and OS showed the same 258 directionality – favorable affects in the original cohort were also favorable in synthetic cohorts and vice 259 *versa* – and significance – effects that were significant in the original cohort were also significant in 260 synthetic cohorts and vice versa (except for del(5q) being significantly associated with failure to achieve CR in the original cohort while this effect turned out to be non-significant in the NFlow-generated 261 262 cohort). Importantly, no inverse effects – a variable that would be favorable in the original cohort would

be adverse in a synthetic cohort or *vice versa* – were observed. Detailed outcomes per variable are
reported for CR (Tab. S6), EFS (Tab. S7), and OS (Tab. S8).

265

266 Synthetically generated cohorts safeguard real patient data and prohibit re-identification

Privacy conservation was measured by: i) number of exact matches between original and synthetic 267 cohorts, ii) a privacy leakage coefficient based on Hamming distance, and iii) absolute Hamming 268 269 distances showing the number of variables to be altered per synthetic patient to match a real patient. First, for both synthetic data sets the number of exact matches compared to the original cohort was zero. 270 271 Second, the average minimum distances compared between datapoints in training and test sets were 272 similar for the original cohort, as well as synthetic data from both CTAB-GAN+ and NFlow (Tab. 3). The privacy leakage coefficient – the quotient of Hamming distances between synthetic to test divided 273 274 by synthetic to training data where small values (< 0.05) indicate a small difference between the distances 275 of synthetic data to training and test data, and therefore, indicate no privacy breach - was very low for 276 both CTAB-GAN+ and NFlow (Tab. 3). This signals a low likelihood of re-identification for both 277 synthetic datasets. Third, the median number of variables that would have to be altered to assign a synthetic patient to a training set patient was nine for both CTAB-GAN+ and NFlow. 278

279

280 **Discussion**

281 Synthetic data provide an attractive solution to circumvent issues in current standards of data collection 282 and sharing. These issues encompass first and foremost the time- and cost-intensive data collection 283 process that usually involves enrollment of patients in prospective clinical trials presenting everincreasing costs both regarding funding and time until completion, as well as ethical concerns inherent 284 in clinical research with human subjects.(3,4) The prospect of using synthetic data as a novel kind of 285 control group in prospective trials while effectively alleviating the need to enroll a larger number of 286 287 patients and cutting costs bears the question of how closely such synthetic control arms match realworld cohorts. We used two generative AI technologies, a state-of-the-art GAN, CTAB-GAN+, and 288 289 NFlow, to mimic the distribution of patient variables from four different previously conducted

290 prospective multicenter trials including a total of 1606 patients with AML. Both models demonstrated 291 high performance in previously established evaluation metrics that assess fidelity and usability of 292 synthetic tabular data.(23,24) The comparison of distributions per variable between original and real 293 data further showed close resemblances. Notably, even for statistically significant deviations from the 294 original cohort, differences in effect sizes (e.g. age difference, difference in rates of occurrence for 295 genetic alterations etc.) were often small. Inherent to hypothesis testing with such large sample sizes, 296 even clinically irrelevant deviations can yield statistically significant differences. Importantly, inter-297 variable relationships were conserved in synthetic data: In univariable analyses both effect direction and 298 statistical significance was well captured by both generative models effectively enabling explorative 299 investigations in such data sets.

300 Once real data is obtained, privacy concerns often inhibit public access and thus impede data sharing 301 and third-party hypothesis testing. Frequently used practices range from de-identifying or anonymizing 302 data to more advanced computational approaches. De-identification or anonymization (e.g. removing 303 names and birth dates), as well as adding artificial noise to the original data have recently been proven 304 to be unsafe in terms of guarding privacy as reidentification attacks can successfully unveil patients' 305 identity.(28-30) Computational advances in both federated(31) and swarm learning(32) where machine 306 learning models are trained across multiple locations and only either models or weights are shared rather 307 than the data itself provide a viable alternative. Nevertheless, these technologies are vulnerable to data reconstructions, e.g. via data leakage from model gradients.(33-35) Inherent to synthetic data generation 308 309 in terms of privacy safeguards is a trade-off between usability and privacy where an increase in each 310 negatively affects the other. (36) Ideally, synthetic data should not be re-identifiable but at the same time 311 closely match the original distributions. Zero exact matches were observed in our synthetic cohorts. 312 Additionally, Hamming distances showed that reconstruction of original training samples is highly 313 unlikely given the number of variables per synthetic patient that would have to be altered in order to 314 match a training cohort patient.

The generation of synthetic data is, as all machine learning models are, fundamentally limited by the data that the model is trained on. This implies that external users should be aware of the properties of

317 the training data that went into the generation of a synthetic data set in order to either select the right 318 data set for their research question or vice versa, adapt the research question to the available data. It is 319 therefore important to note, that patients in our trials have all been treated with intensive anthracycline-320 based therapy and largely stem from a Middle-European ethnic background. Hence, our generated 321 synthetic AML data sets may not fully capture features of other populations let alone other treatment 322 modalities, such as less intensive therapy or targeted agents. The incorporation of these modalities will 323 be addressed in future works. Since ML models thrive on large and diverse data sets, synthetic data 324 generation from medical records is caught in a paradoxical loop: Available data is sparse, synthetic data can potentially accommodate for sparse available real data, synthetic data requires large and diverse sets 325 of real data to meaningfully represent the population.(37) Therefore, the generation of synthetic data is 326 327 likely more robust, if training data from large multicenter cohorts is used. Nonetheless, the availability 328 of synthetic data promises a democratization of clinical research. In similar efforts, Azizi et al.(38) and 329 D'Amico et al.(39) explored synthetic data generation in cancer. Azizi et al.(38) used data from a 330 previously conducted clinical trial in colorectal cancer to generate synthetic data using conditional 331 decision trees. Focusing on myelodysplastic neoplasms (MDS), D'Amico et al.(39) used a conditional 332 Wasserstein tabular GAN to generate synthetic MDS patients from the GenoMed4All database. Both groups conclude the feasibility of either method to generate synthetic data that closely resemble the 333 334 original data distributions and provide access to their synthetic data. Such studies may alleviate a 335 common gatekeeping mechanism of costly data collection efforts that are often restricted to large well-336 funded medical centers. Further, this also extends to cross-domain applications involving medical data, 337 e.g. the training of a ML model by a third party that requires large sets of training data.

In summary, we demonstrate the feasibility of two different technologies of generative AI to create synthetic clinical trial data that both closely mimic disease biology and clinical behavior, as well as conserve the privacy of patients in the training cohort. Generating such large synthetic data sets based on multicenter clinical trial training data holds the promise of enabling a new kind of clinical research improving upon data accessibility, while ameliorating current hindrances in data sharing.

344 Acknowledgements

- 345 We thank all contributing physicians, laboratories, and nurses associated with the German Study
- 346 Alliance Leukemia and especially participating patients for their valuable contributions.

347

348 Authorship Contributions

- 349 J.-N.E., W.H., M.W., and J.M.M. designed the study. J.-N.E., C.R, U.P., C. M.-T., H.S., C.D.B., C.S.,
- 350 K.S-E., M.H., M.K., A.B., C.T., J.S., M.B., and J.M.M. provided patient samples. S.S. and C.T.
- 351 performed molecular analysis. W.H. trained generative models. J.-N.E. performed statistical analysis
- and wrote the initial draft. All authors had access to all of the data, analyzed the data, provided critical
- scientific insights and revised the draft. All authors agreed to the final version of the manuscript and the
- decision to submit it for publication.

355

356 Disclosure of Conflicts of Interest

- 357 The authors declare no competing interests.
- 358

359 **References**

- The Cancer Genome Atlas Program National Cancer Institute [Internet]. 2018 [cited 2020 Sep
 1]. Available from: https://www.cancer.gov/about-nci/organization/ccg/research/structural genomics/tcga
- Taitsman JK, Grimm CM, Agrawal S. Protecting Patient Privacy and Data Security. New England
 Journal of Medicine. 2013 Mar 14;368(11):977–9.
- Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, et al. The
 importance of greater speed in drug development for advanced malignancies. Cancer Med. 2018
 Mar 30;7(5):1824–36.
- Martin L, Hutchens M, Hawkins C, Radnov A. How much do clinical trials cost? Nature Reviews
 Drug Discovery. 2017 Jun 1;16(6):381–2.
- Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. New England Journal of
 Medicine. 2015 Sep 17;373(12):1136–52.

- Estey E, Othus M, Gale RP. New study-designs to address the clinical complexity of acute myeloid
 leukemia. Leukemia. 2019 Mar;33(3):567–9.
- Goodfellow IJ, Pouget-Abadie J, Mirza M, Xu B, Warde-Farley D, Ozair S, et al. Generative
 Adversarial Networks [Internet]. arXiv; 2014 [cited 2022 Jul 21]. Available from:
 http://arxiv.org/abs/1406.2661
- Kazeminia S, Baur C, Kuijper A, van Ginneken B, Navab N, Albarqouni S, et al. GANs for medical
 image analysis. Artificial Intelligence in Medicine. 2020 Sep 1;109:101938.
- Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M, et al. A novel
 prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients
 entered into the prospective AML96 trial. Blood. 2010 Aug 12;116(6):971–8.
- Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, et al. High-dose cytarabine
 consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia:
 results of the prospective randomized AML2003 trial. J Clin Oncol. 2013 Jun 10;31(17):2094–102.
- Röllig C, Kramer M, Gabrecht M, Hänel M, Herbst R, Kaiser U, et al. Intermediate-dose cytarabine
 plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid
 leukemia in elderly patients. Ann Oncol. 2018 01;29(4):973–8.
- Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, et al. Addition of sorafenib
 versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed
 acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet
 Oncol. 2015 Dec;16(16):1691–9.
- World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles
 for Medical Research Involving Human Subjects. JAMA. 2013 Nov 27;310(20):2191–4.
- Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and
 Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel.
 Blood. 2022 Jul 7;blood.2022016867.
- Stasik S, Schuster C, Ortlepp C, Platzbecker U, Bornhäuser M, Schetelig J, et al. An optimized
 targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide
 variants. Biomol Detect Quantif. 2018 May;15:6–12.
- 16. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3activating mutations in 979 patients with acute myelogenous leukemia: association with FAB
 subtypes and identification of subgroups with poor prognosis. Blood. 2002 Jun 15;99(12):4326–
 35.
- Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic
 impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood.
 2006 May 15;107(10):4011–20.
- 18. Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, et al. CEBPA Mutations in 4708
 Patients with Acute Myeloid Leukemia Differential Impact of bZIP and TAD Mutations on
 Outcome. Blood. 2021 Jul 28;blood.2020009680.
- 410 19. Zhao Z, Kunar A, Birke R, Chen LY. CTAB-GAN+: Enhancing Tabular Data Synthesis [Internet].
 411 arXiv; 2022 [cited 2023 Jul 24]. Available from: http://arxiv.org/abs/2204.00401

- 412 20. Goodfellow IJ, Pouget-Abadie J, Mirza M, Xu B, Warde-Farley D, Ozair S, et al. Generative
 413 Adversarial Networks. arXiv:14062661 [cs, stat] [Internet]. 2014 Jun 10 [cited 2021 May 27];
 414 Available from: http://arxiv.org/abs/1406.2661
- 21. Papamakarios G, Nalisnick E, Rezende DJ, Mohamed S, Lakshminarayanan B. Normalizing Flows
 for Probabilistic Modeling and Inference [Internet]. arXiv; 2021 [cited 2023 Jul 24]. Available
 from: http://arxiv.org/abs/1912.02762
- 418 22. Qian Z, Cebere BC, van der Schaar M. Synthcity: facilitating innovative use cases of synthetic data
 419 in different data modalities [Internet]. arXiv; 2023 [cited 2023 Jul 24]. Available from:
 420 http://arxiv.org/abs/2301.07573
- 421 23. Chundawat VS, Tarun AK, Mandal M, Lahoti M, Narang P. TabSynDex: A Universal Metric for
 422 Robust Evaluation of Synthetic Tabular Data [Internet]. arXiv; 2022 [cited 2023 Jul 24]. Available
 423 from: http://arxiv.org/abs/2207.05295
- 424 24. Norcliffe A, Cebere B, Imrie F, Lio P, van der Schaar M. SurvivalGAN: Generating Time-to-Event
 425 Data for Survival Analysis [Internet]. arXiv; 2023 [cited 2023 Aug 3]. Available from:
 426 http://arxiv.org/abs/2302.12749
- Platzer M, Reutterer T. Holdout-Based Fidelity and Privacy Assessment of Mixed-Type Synthetic
 Data [Internet]. arXiv; 2021 [cited 2023 Aug 10]. Available from: http://arxiv.org/abs/2104.00635
- 429 26. Hamming RW. Error detecting and error correcting codes. The Bell System Technical Journal.
 430 1950 Apr;29(2):147–60.
- 431 27. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991 Jan;9(1):191–2.
- 432 28. Emam KE, Jonker E, Arbuckle L, Malin B. A Systematic Review of Re-Identification Attacks on
 433 Health Data. PLOS ONE. 2011 Dec 2;6(12):e28071.
- 434 29. Ursin G, Sen S, Mottu JM, Nygård M. Protecting Privacy in Large Datasets-First We Assess the
 435 Risk; Then We Fuzzy the Data. Cancer Epidemiol Biomarkers Prev. 2017 Aug 1;26(8):1219–24.
- 30. Sweeney L, Yoo JS, Perovich L, Boronow KE, Brown P, Brody JG. Re-identification Risks in HIPAA
 Safe Harbor Data: A study of data from one environmental health study. Technol Sci.
 2017;2017:2017082801.
- 439 31. Rieke N, Hancox J, Li W, Milletarì F, Roth HR, Albarqouni S, et al. The future of digital health with
 440 federated learning. npj Digit Med. 2020 Sep 14;3(1):1–7.
- Warnat-Herresthal S, Schultze H, Shastry KL, Manamohan S, Mukherjee S, Garg V, et al. Swarm
 Learning for decentralized and confidential clinical machine learning. Nature. 2021
 Jun;594(7862):265–70.
- 33. Melis L, Song C, De Cristofaro E, Shmatikov V. Exploiting Unintended Feature Leakage in
 Collaborative Learning [Internet]. arXiv; 2018 [cited 2023 Jul 10]. Available from:
 http://arxiv.org/abs/1805.04049
- 34. Zhu L, Liu Z, Han S. Deep Leakage from Gradients [Internet]. arXiv; 2019 [cited 2023 Jul 10].
 Available from: http://arxiv.org/abs/1906.08935

- 35. Boenisch F, Dziedzic A, Schuster R, Shamsabadi AS, Shumailov I, Papernot N. When the Curious
 Abandon Honesty: Federated Learning Is Not Private [Internet]. arXiv; 2023 [cited 2023 Jul 10].
 Available from: http://arxiv.org/abs/2112.02918
- 452 36. Rajotte JF, Bergen R, Buckeridge DL, El Emam K, Ng R, Strome E. Synthetic data as an enabler for 453 machine learning applications in medicine. iScience. 2022 Nov 18;25(11):105331.
- 454 37. Chen RJ, Lu MY, Chen TY, Williamson DFK, Mahmood F. Synthetic data in machine learning for 455 medicine and healthcare. Nat Biomed Eng. 2021 Jun;5(6):493–7.
- 456 38. Azizi Z, Zheng C, Mosquera L, Pilote L, Emam KE. Can synthetic data be a proxy for real clinical
 457 trial data? A validation study. BMJ Open. 2021 Apr 1;11(4):e043497.
- 458 39. D'Amico S, Dall'Olio D, Sala C, Dall'Olio L, Sauta E, Zampini M, et al. Synthetic Data Generation by
 459 Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology. JCO Clinical
 460 Cancer Informatics. 2023 Jul;(7):e2300021.
- 461

462 **Tables**

clinical data	original cohort	CTAB-GAN+	р	NFlow	р
number of patients	1606	1606		1606	
age, median (IQR)	56 (44 - 65)	53 (42 - 64)	0.0001	58 (47 - 66)	0.039
sex, n (%)			0.023		0.672
female	768 (47.8)	703 (43.8)		781 (48.6)	
male	838 (52.2)	903 (56.2)		825 (51.4)	
AML status, n (%)					
de novo	1339 (83.4)	1339 (83.4)	1.000	1250 (77.8)	0.041
secondary	195 (12.1)	193 (12.0)	0.914	200 (12.5)	0.554
therapy-associated	54 (3.4)	57 (3.5)	0.847	83 (5.2)	0.007
extramedullary disease, n (%)	224 (13.9)	228 (14.2)	0.409	279 (17.4)	0.003
laboratory values					
WBC, median (IQR) in GPt/l	19.5 (4.5 - 53.4)	27.0 (8.3 - 69.6)	<0.0001	14.4 (5.8 - 55.3)	0.832
Hb, median (IQR) in mmol/l	5.9 (5.0 - 8.6)	5.8 (5.0 - 7.0)	0.949	5.9 (5.2 - 6.8)	0.988
Plt, median (IQR) in GPt/l	50.0 (27.0 - 94.0)	49.7 (31.0 - 93.4)	0.073	48.0 (26.2 – 94.5)	0.405

463 **Table 1 Distribution of baseline characteristics between the original and synthetic cohort.** Boldface

464 indicates statistical significance (p < 0.05). *p*-values are calculated using two-sample comparisons 465 between each of the synthetic cohorts and the baseline cohort for reference. Abbreviations: Hb: 466 hemoglobin; IQR: interquartile range; n: number; Plt: platelet count; WBC: white blood cell count.

467

	original cohort	CTAB-GAN+	NFlow
CR after induction therapy, n (%)	1135 (70.7)	1184 (73.7)	1110 (69.1)
OR	2.41	2.81	2.24
[95%-CI]	[2.16 - 2.68]	[2.51 - 3.14]	[2.01 - 2.49]
<i>p</i> -value		0.059	0.356
median EFS, months (IQR)	7.2 (6.5 – 8.0)	12.8 (11.8 – 14.1)	9.0 (8.3 – 9.7)
HR	1.36	0.74	0.87
[95%-CI]	[1.25 - 1.47]	[0.68 - 0.80]	[0.80 - 0.94]
<i>p</i> -value		<0.0001	<0.0001
median OS, months (IOR)	17.5 (15.7 – 19.2)	19.5 (15.7 – 19.2)	16.2 (15.7 – 19.2)
HR	1.14	0.88	1.00
[95%-CI]	[1.04 - 1.24]	[0.81- 0.96]	[0.92 - 1.09]
<i>p</i> -value		<0.0001	0.055

468Table 2 Comparison of patient outcomes between the original and synthetic cohort. Logistic469regression and Cox proportional hazard models were used to obtain odds ratios (OR) for achievement470of complete remission (CR) and hazard ratio (HR) with corresponding 95%-confidence intervals (95%-471CI). Boldface indicates statistical significance (p < 0.05). p-values are calculated using two-sample472comparisons between each of the synthetic cohorts and the original cohort for reference. Other473abbreviations: n: number.

474

475

476

477

	CTAB-GAN+	NFlow	original cohort
absolute Hamming distances			~~~~
average min. distance train	8.7034	9.3474	8.2524
average min. distance test	8.8587	9.4117	8.2224
median distance train	9	9	8
median distance test	9	9	8
relative Hamming distances			
privacy leakage coefficient	0.0178	0.0069	

Table 3 Hamming distances for privacy conservation. Hamming distances were used to measure the 479 480 distance between two points within and between equally sized subsets of training (four sets of 20%) and 481 test data (20%). The median distance represents the number of variables that have to be altered (and 482 matched exactly) to fit a real patient. A threshold for the privacy leakage coefficient of 0.05 for relative 483 distances was set where values above 0.05 signal potential privacy breaches. Both synthetic data sets fell well below the 0.05 threshold signaling larger distances between synthetic and training data, which 484 make a re-identification of training set patients unlikely. 485

486



Figures and Figure Legends 488



490

491 Figure 1 Distribution of molecular and cytogenetic alterations between real and synthetic patients. 492 50 molecular genetic and cytogenetic alterations were included in generative modeling. Molecular 493 genetics were originally assessed by next-generation sequencing using a targeted myeloid panel including genes that encode for epigenetic regulators (A, dark blue), the cohesion complex (B, orange), 494 transcription factors (C, red), NPM1 and TP53 (D, light blue), signaling factors (E, purple), and the 495 spliceosome (F, green). Cytogenetic aberrations (G, black) were selected based on previously 496 497 demonstrated impact on patient outcomes. Distributions for all variables are denoted as percentages of 498 each respective cohort. Overall, both synthetic cohorts well represented the distribution of alterations in 499 the original cohort with only slight deviations denoted by highly statistically significant (p < 0.001) 500 differences in BCORL1, DNMT3A, PHF6, and ZRSR2 for NFlow, as well as CUX1 and GATA2 for 501 CTAB-GAN+.





Figure 2 Heatmaps for relative differences of genetic associations. The difference in co-occurrences 503 504 of genetic alterations are plotted. Relative increases (red) or decreases (blue) are displayed on a scale 505 from -100% to + 100%. The overlap between the original cohort and CTAB-GAN+ (A), as well as 506 original and NFlow (B) showed high congruency. Increases or decreases in co-occurring genetic 507 alterations were commonly found to affect alterations with low frequency in the original cohort.



Overall survival



- **Figure 3 Comparison of survival curves between original and synthetic cohorts**. Event-free survival (EFS) deviated significantly from the original cohort for both synthetic cohorts (A). For the NFlowgenerated cohort, there was no significant deviation from the original distribution for overall survival (OS), while the CTAB-GAN+-generated cohort again differed significantly (B). Interestingly, while the survival curve for CTAB-GAN+ displays a plausible curve up until ten years of follow-up, the curve shows no stabilization of survival rates in the end as the original cohort does. Contrastingly, the survival curve for NFlow shows an overall plausible course, however, NFlow tends to overtly censor patients
- 517 after two years of follow-up.